Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021
![](/report_cover/8047/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Methicillin-Resistant Staphylococcus Aureus Infections: Overview
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections. Genetically diverse, the epidemiology of MRSA is primarily characterized by the serial emergence of epidemic strains. Although its incidence has recently declined in some regions, MRSA still poses a formidable clinical threat, with persistently high morbidity and mortality. Successful treatment remains challenging and requires the evaluation of both novel antimicrobials and adjunctive aspects of care, such as infectious disease consultation, echocardiography and source control.
'Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape is provided which includes the disease overview and Methicillin-Resistant Staphylococcus Aureus Infections treatment guidelines. The assessment part of the report embraces, in depth Methicillin-Resistant Staphylococcus Aureus Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Methicillin-Resistant Staphylococcus Aureus Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs
Further product details are provided in the report
Methicillin-Resistant Staphylococcus Aureus Infections: Therapeutic Assessment
This segment of the report provides insights about the different Methicillin-Resistant Staphylococcus Aureus Infections drugs segregated based on following parameters that define the scope of the report, such as:
Methicillin-Resistant Staphylococcus Aureus Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Methicillin-Resistant Staphylococcus Aureus Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Methicillin-Resistant Staphylococcus Aureus Infections drugs.
Methicillin-Resistant Staphylococcus Aureus Infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Methicillin-Resistant Staphylococcus Aureus Infections: Overview
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections. Genetically diverse, the epidemiology of MRSA is primarily characterized by the serial emergence of epidemic strains. Although its incidence has recently declined in some regions, MRSA still poses a formidable clinical threat, with persistently high morbidity and mortality. Successful treatment remains challenging and requires the evaluation of both novel antimicrobials and adjunctive aspects of care, such as infectious disease consultation, echocardiography and source control.
'Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape is provided which includes the disease overview and Methicillin-Resistant Staphylococcus Aureus Infections treatment guidelines. The assessment part of the report embraces, in depth Methicillin-Resistant Staphylococcus Aureus Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Methicillin-Resistant Staphylococcus Aureus Infections R&D. The therapies under development are focused on novel approaches to treat/improve Methicillin-Resistant Staphylococcus Aureus Infections.
This segment of the Methicillin-Resistant Staphylococcus Aureus Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs
- TRL1068: Trellis Bioscience
- Delpazolid (LCB01-0371): LegoChem Biosciences
Further product details are provided in the report
Methicillin-Resistant Staphylococcus Aureus Infections: Therapeutic Assessment
This segment of the report provides insights about the different Methicillin-Resistant Staphylococcus Aureus Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Methicillin-Resistant Staphylococcus Aureus Infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Methicillin-Resistant Staphylococcus Aureus Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Methicillin-Resistant Staphylococcus Aureus Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Methicillin-Resistant Staphylococcus Aureus Infections drugs.
Methicillin-Resistant Staphylococcus Aureus Infections Report Insights
- Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Methicillin-Resistant Staphylococcus Aureus Infections drugs?
- How many Methicillin-Resistant Staphylococcus Aureus Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Methicillin-Resistant Staphylococcus Aureus Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Methicillin-Resistant Staphylococcus Aureus Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Methicillin-Resistant Staphylococcus Aureus Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Trellis Bioscience
- LegoChem Biosciences
- Aptorum Group
- Allergan
- iNtRON Biotechnology
- Neupharma
- ImmuPharma
- Lytix Biopharma
- CrystalGenomics
- AIMM Therapeutics
- Madam Therapeutics
- ContraFect
- Aphios
- Cellics Therapeutics
- GlaxoSmithKline
- Kyorin Pharmaceuticals
- Motif Bio
- MicuRx
- Oxford Antibiotic Group
- Destiny Pharma
- TSRL, Inc.
- TAXIS Pharmaceuticals
- Aridis Pharmaceuticals
- Acurx Pharmaceuticals
- Agile Biotics
- Integrated BioTherapeutics
- Biocidium Biopharmaceuticals Inc.
- Azitra
- TRL1068
- Delpazolid
- ALS 4
- Dalbavancin
- Tonabacase
- Teicoplanin inhalation
- Research programme: antibacterials
- LTX 109
- CG 400549
- Research programme: anti-infective monoclonal antibodies
- SAAP 148
- Exebacase
- Marinus
- CTI 005
- Gepotidacin
- KRP-AM1977Y
- Iclaprim
- MRX 4
- MRX 7
- TetramOX
- XF-73
- TXA709
- ARV-1801
- AR-301
- ACX-375C
- ABX-605
- IBT-V02
- BCM-0184
Introduction
Executive Summary
Methicillin-Resistant Staphylococcus Aureus Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Methicillin-Resistant Staphylococcus Aureus Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Methicillin-Resistant Staphylococcus Aureus Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Methicillin-Resistant Staphylococcus Aureus Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Tonabacase: iNtRON Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
TRL1068: Trellis Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
Methicillin-Resistant Staphylococcus Aureus Infections Key Products
Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
Appendix
Executive Summary
Methicillin-Resistant Staphylococcus Aureus Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Methicillin-Resistant Staphylococcus Aureus Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Methicillin-Resistant Staphylococcus Aureus Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Methicillin-Resistant Staphylococcus Aureus Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Tonabacase: iNtRON Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
TRL1068: Trellis Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
Methicillin-Resistant Staphylococcus Aureus Infections Key Products
Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Methicillin-Resistant Staphylococcus Aureus Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Methicillin-Resistant Staphylococcus Aureus Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Methicillin-Resistant Staphylococcus Aureus Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Methicillin-Resistant Staphylococcus Aureus Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products